Tiziana Life Sciences (NASDAQ:TLSA) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Tiziana Life Sciences (NASDAQ:TLSA) from a hold rating to a sell rating in a report released on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tiziana Life Sciences in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Tiziana Life Sciences presently has an average rating of “Sell”.

Tiziana Life Sciences Trading Down 2.4%

Shares of TLSA opened at $1.21 on Friday. The stock has a fifty day moving average price of $1.32 and a two-hundred day moving average price of $1.57. Tiziana Life Sciences has a 52-week low of $1.01 and a 52-week high of $2.60.

Institutional Investors Weigh In On Tiziana Life Sciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Cubist Systematic Strategies LLC bought a new stake in shares of Tiziana Life Sciences during the first quarter worth $25,000. Rachor Investment Advisory Services LLC bought a new stake in shares of Tiziana Life Sciences during the fourth quarter worth $25,000. Bison Wealth LLC bought a new stake in shares of Tiziana Life Sciences during the fourth quarter worth $30,000. HRT Financial LP bought a new stake in shares of Tiziana Life Sciences during the fourth quarter worth $36,000. Finally, Marshall Wace LLP bought a new stake in shares of Tiziana Life Sciences during the second quarter worth $39,000.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.